Recent attention on Zevra Therapeutics (ZVRA) centers on its first quarter 2026 earnings, where sales and net income figures shifted sharply, and earnings per share turned positive compared with a loss a year earlier.

Those earnings and the recent SDX portfolio sale have come alongside a 30 day share price return of 14.4% and a 90 day share price return of 32.38%, while the 3 year total shareholder return of 127.4% points to momentum that has been building over a longer period.

If Zevra’s rare disease focus has your attention, you may also want to see where the next potential opportunities in healthcare AI could be hiding with our 33 healthcare AI stocks

With earnings firmly in the black and the stock trading at a steep discount to an implied US$23 target, is the current US$11.12 price still underestimating Zevra’s rare disease pipeline, or is the market already accounting for future growth?

Most Popular Narrative: 58.6% Undervalued

The leading narrative on Zevra sets a fair value of $26.89 against the last close at $11.12, framing the current price as a deep discount to its rare disease portfolio.

Zevra Therapeutics is at the most profitable inflection point in biotechnology: the transition from cash-burning R&D to cash-generating commercial sales. With the recent FDA approval of Miplyffa (for Niemann-Pick disease type C), Zevra has secured the first and only approved treatment for this ultra-rare condition. Combined with the sale of its Priority Review Voucher (PRV) for ~$100M non-dilutive cash, the balance sheet is fortified. The market is currently pricing ZVRA as a speculative biotech, failing to account for the high-margin, recurring revenue of a rare disease monopoly.

Curious what kind of revenue ramp, margin profile, and future earnings multiple are baked into that gap between $11.12 and $26.89? The narrative leans on rare disease pricing power, a concentrated pipeline, and projected profitability to justify that valuation path, but the exact mix of assumptions is where the real story sits.

Result: Fair Value of $26.89 (UNDERVALUED)

However, the narrative depends heavily on a single ultra rare asset and optimistic royalty and pricing assumptions, so any regulatory, reimbursement or commercial setback could quickly challenge it.

Next Steps

If this mix of optimism and concern feels finely balanced, it is a good time to move fast, review the numbers, and test your own thesis using the 5 key rewards and 1 important warning sign tool.

Looking for more investment ideas?

Now is the moment to broaden your watchlist, compare different types of opportunities, and give yourself more options before the next wave of market moves.

• Spot potential high risk, high reward opportunities early by scanning 28 elite penny stocks with strong financials that already show stronger financial footing than most micro caps.
• Zero in on quality at a discount by using the 47 high quality undervalued stocks to find companies that pair solid cash flows with prices that look out of sync with fundamentals.
• Prioritise resilience by filtering for 68 resilient stocks with low risk scores that score well on stability so short term volatility is less likely to derail your long term plan.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.